Changes in the Epidemiology of Diabetic Retinopathy in Spain: A Systematic Review and Meta-Analysis

P. ROMERO-AROCA, M. LOPEZ-GALVEZ, M. MARTINEZ-BROCCA, A. PAREJA-RIOS, S. ARTOLA, J. FRANCH-NADAL, J. FERNANDEZ-BALLART, J. ANDONEGUI and M. BAGET-BERNALDIZ
Healthcare. 2022 Jul 1; . doi:10.3390/healthcare10071318; PMID:35885844

• Any: 01/07/2022
• FI: 2.8
• Article

The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials

J. FRANCH-NADAL, S. MALKIN, B. HUNT, V. MARTIN, M. ESTEBANEZ and J. VIDAL
ADVANCES IN THERAPY. 2022 Jul 1; . doi:10.1007/s12325-022-02156-8; PMID:35553372

• Any: 01/07/2022
• FI: 3.8
• Article

2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care

S. SEIDU, X. COS, S. BRUNTON, S. HARRIS, S. JANSSON, M. MATA-CASES, A. NEIJENS, P. TOPSEVER and K. KHUNTI
Primary Care Diabetes. 2022 Apr 1; . doi:10.1016/j.pcd.2022.02.002; PMID:35183458

• Any: 01/04/2022
• FI: 2.9
• Article

Compliance with the DPP-4 inhibitors dose adjustment recommendations based on renal function in a population database.

Franch-Nadal J, Gatius JR, Mata-Cases M, Ortega E, Valles JA, Vlacho B and Mauricio D
Endocrinologia Diabetes y Nutricion. 2022 Feb 28; . doi:10.1016/j.endien.2022.02.011; PMID:35256063

• Any: 28/02/2022
• FI: 1.9
• Article

Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study

A. MOLLO, B. VLACHO, M. GRATACOS, M. MATA-CASES, E. RUBINAT, A. BERENGUERA, J. REAL, R. PUIG-TRESERRA, X. COS, J. FRANCH-NADAL, K. KHUNTI, D. MAURICIO and INTEGRA Res grp
DIABETES OBESITY & METABOLISM. 2023 Apr 1; . doi:10.1111/dom.14951; PMID:36546592

• Any: 01/04/2023
• FI: 5.4
• Article